Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for iBio (IBIO) over the last 10 years, with Q4 2025 value amounting to $1.2 million.

  • iBio's Current Deferred Revenue rose 9166.67% to $1.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 million, marking a year-over-year increase of 9166.67%. This contributed to the annual value of $1.2 million for FY2025, which is 50000.0% up from last year.
  • According to the latest figures from Q4 2025, iBio's Current Deferred Revenue is $1.2 million, which was up 9166.67% from $1.2 million recorded in Q3 2025.
  • iBio's Current Deferred Revenue's 5-year high stood at $1.2 million during Q2 2025, with a 5-year trough of $8000.0 in Q1 2022.
  • In the last 4 years, iBio's Current Deferred Revenue had a median value of $300000.0 in 2024 and averaged $455937.5.
  • In the last 5 years, iBio's Current Deferred Revenue tumbled by 9909.71% in 2022 and then surged by 50000.0% in 2025.
  • Over the past 4 years, iBio's Current Deferred Revenue (Quarter) stood at $60000.0 in 2021, then surged by 46.67% to $88000.0 in 2022, then surged by 581.82% to $600000.0 in 2024, then surged by 91.67% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q4 2025, $1.2 million for Q3 2025, and $1.2 million during Q2 2025.